Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

• Alastair J. King,

  Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

  ⨯
• Marc R. Arnone,

  Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

  ⨯
• Maureen R. Bleam,

  Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

  ⨯
• Katherine G. Moss,

  Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

  ⨯
• Jingsong Yang,

  Affiliation GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America

  ⨯
• Kelly E. Fedorowicz,

  Affiliation GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America

  ⨯
• Kimberly N. Smitheman,

  Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

  ⨯
• Joseph A. Erhardt,

  Current address: Janssen Oncology R&D, Radnor, Pennsylvania, United States of America

  Affiliation GlaxoSmithKline Portfolio Management, Collegeville, Pennsylvania, United States of America

  ⨯
• Angela Hughes-Earle,

  Affiliation GlaxoSmithKline Department of Safety Assessment, King of Prussia, Pennsylvania, United States of America

  ⨯
• Laurie S. Kane-Carson,

  Affiliation GlaxoSmithKline Department of Screening & Compound Profiling, GlaxoSmithKline, Durham, North Carolina, United States of America

  ⨯
• Robert H. Sinnamon,

  Affiliation GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America

  ⨯
• Hongwei Qi,

  Affiliation GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America

  ⨯
• Tara R. Rheault,

  Affiliation GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America

  ⨯
• David E. Uehling,

  Current address: Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada

  Affiliation GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America

  ⨯
• Sylvie G. Laquerre

  * E-mail: sylvie.g.laquerre@gsk.com

  Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

  ⨯